logoslogan
home4.jpg

We are a venture capital firm investing in life science companies covering start-ups to later stage companies. Based in Heidelberg, we invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment modalities and pharmaceuticals, next generation enabling technology platforms or innovations in the diagnostics and medical device area. As an independent and focused team we move quickly with short decision timelines. However, once engaged, we offer our portfolio companies the time and the attention they deserve to make them sucessful.

EMBL Ventures manages two Funds with a total of € 68m capital on behalf of major European private and institutional investors. We prefere a role as lead or co-lead investor in  financing rounds which typically range from € 5m to € 30m. Our total commitment in a single portfolio company can go as high as € 8m.

As with our portfolio companies each Partner at EMBL Ventures strives to build long-lasting personal relationships with Investors in our Funds, such as institutionals, high net-worth individuals and familiy offices. These relationships are based on EMBL Ventures' core values of open and prompt communication coupled with the ambition to generate maximum return.

Successful Spin-Out of ImevaX GmbH from the Technische Universität München
(TUM) and funding by the Federal Ministry of Education and Research (BMBF) with EURO 5.9 million

A key factor for the success of the founder Professor Markus Gerhard and his team, is the long-standing support from the Institute of Medical Microbiology, Immunology and Hygiene at the TUM under the leadershipof Professor Dirk Busch and funding from the Federal Ministry of Education and Research (BMBF).

Continue Reading

EU-funded consortium led by immatics and BioNTech to advance a novel class of fully personalized therapeutic cancer vaccines into clinical trials for brain cancer

Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC). First centers to enroll glioblastoma patients opened in Heidelberg and Tuebingen
European Union supports the initiative with a €6 million grant


Continue Reading

EMBL Ventures Invests £2M ($3.3M) in a Second Close of Crescendo Biologics’ Series A Financing

£19.5M raised to drive development of best-in-class fully human VH antibody fragment therapeutics

Cambridge, UK. 3rd April 2014 – Crescendo Biologics Limited (Crescendo) today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing.

Continue Reading